

THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS IN WHOLE OR IN PART. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN MODUS THERAPEUTICS HOLDING AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.

## **Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue of Units**

The Board of Directors of Modus Therapeutics Holding AB ("Modus" or the "Company") has, in connection with the rights issue of units announced on June 26, 2025 (the "Rights Issue"), prepared a Swedish language EU Growth Prospectus (the "Prospectus") which today has been approved and registered by the Swedish Financial Supervisory Authority.

### **Publication of Prospectus**

The Prospectus has been prepared in connection with the Rights Issue and has today, on August 11, 2025, been approved and registered with the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and instructions, as well as subscription forms, is available on the Company's website ([www.modustx.com](http://www.modustx.com)) and on the website of Bergs Securities ([www.bergssecurities.se](http://www.bergssecurities.se)). The Prospectus will also be available on the website of the Swedish Financial Supervisory Authority ([www.fi.se](http://www.fi.se)).

### **Summary of the Rights Issue**

- One (1) existing share in the Company on the record date, which was on August 8, 2025, entitles to one (1) unit right. Four (4) unit rights entitle the holder to subscribe for one (1) unit consisting of nine (9) shares, three (3) warrants of series TO 2026 and four (4) warrants of series TO 2030
- The subscription price is SEK 3.15 per unit, corresponding to SEK 0.35 per new share. The warrants are issued free of charge
- Trading in unit rights will take place during the period from August 12 – August 21, 2025
- The subscription period runs from August 12 – August 26, 2025

The Rights Issue is fully covered by subscription commitments and guarantee undertakings. Neither subscription commitments nor guarantee undertakings are secured by bank guarantees, blocked funds, pledged assets or similar. For further information about the Rights Issue, please refer to the published Prospectus.

**Advisors**

Bergs Securities is sole manager and bookrunner and Advokatfirman Vinge is legal advisor to Modus in connection with the Rights Issue.

**For more information on Modus Therapeutics, please contact:**

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: [john.ohd@modustx.com](mailto:john.ohd@modustx.com)

*The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-11 11:10 CEST.*

**Certified Adviser**

Svensk Kapitalmarknadsgranskning AB

Website: [www.skmg.se](http://www.skmg.se)

**About Modus Therapeutics and sevuparin**

Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at [www.modustx.com](http://www.modustx.com).

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

### **Important Information**

The information contained in this press release does not constitute an offer to acquire, subscribe for, or otherwise trade in shares or other securities in Modus. An invitation to relevant individuals to subscribe for shares in Modus will only be made through the prospectus that Modus will publish. No actions have been taken, or will be taken, by Modus to permit a public offering in any jurisdiction other than Sweden.

This press release may not be made public, published, or distributed, either directly or indirectly, in or into Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, the United Kingdom, South Africa, the United States, or any other jurisdiction where such action would be subject to legal restrictions or would require additional prospectuses, registration, or other measures beyond those required by Swedish law. The information in this press release may not be forwarded or reproduced in a manner that is inconsistent with such restrictions or would entail such requirements. Any violation of these instructions may constitute a breach of applicable securities laws. Neither subscription rights, paid and subscribed shares, nor new shares issued in the offering have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered, or transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act. The offering is also not directed to persons residing in Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, the United Kingdom, South Africa, or any other jurisdiction where participation would require additional prospectuses, registration, or other measures beyond those required by Swedish law.

### **Forward-looking Statements**

This press release contains certain forward-looking statements that reflect Modus' current views and expectations regarding future events, as well as financial and operational performance, including statements relating to the Rights Issue and statements concerning guidance, planning, future prospects, and strategies. Words such as "intends", "assesses", "expects", "plans", "estimates", "may", and other expressions indicating forecasts or predictions regarding future developments or trends and which are not based on historical facts, constitute forward-looking information. Although Modus believes that these statements are based on reasonable assumptions and expectations, Modus cannot guarantee that such forward-looking statements will materialize. As these forward-looking statements involve both known and unknown risks and uncertainties, actual outcomes may differ materially from those expressed in the forward-looking information. Forward-looking statements in this press release apply only as of the date of the press release and may change without notice. Potential investors should not place undue reliance on the forward-looking statements in this press release. Potential investors are strongly recommended to read those sections of the prospectus that contain more detailed descriptions of the factors that may affect the Company's operations and the market in which the Company operates. The Company undertakes no obligation to publicly update or revise forward-looking statements due to new information, future events, or similar circumstances beyond what is required by applicable laws or stock market regulations.

**Attachments**

**Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue of Units**